AgomAb Therapeutics (NASDAQ:AGMB) Issues Quarterly Earnings Results

AgomAb Therapeutics (NASDAQ:AGMB) announced its earnings results on Thursday. The company reported ($0.46) EPS for the quarter, FiscalAI reports.

AgomAb Therapeutics Price Performance

AGMB opened at $14.50 on Friday. The firm’s 50 day moving average is $12.24. AgomAb Therapeutics has a twelve month low of $8.75 and a twelve month high of $17.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.52 and a quick ratio of 6.52.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AGMB. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. HC Wainwright started coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.